SEC Filings

SEC Filings

Filing date	Description	Form	View
Jan 04, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-19-000146.pdf 0001214659-19-000146.rtf 0001214659-19-000146.xls
Jan 04, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-19-000147.pdf 0001214659-19-000147.rtf 0001214659-19-000147.xls
Jan 04, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-19-000148.pdf 0001214659-19-000148.rtf 0001214659-19-000148.xls
Jan 04, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-19-000149.pdf 0001214659-19-000149.rtf 0001214659-19-000149.xls
Jan 04, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-19-000150.pdf 0001214659-19-000150.rtf 0001214659-19-000150.xls
Jan 04, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-19-000151.pdf 0001214659-19-000151.rtf 0001214659-19-000151.xls
Jan 04, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-19-000152.pdf 0001214659-19-000152.rtf 0001214659-19-000152.xls
Jan 04, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-19-000153.pdf 0001214659-19-000153.rtf 0001214659-19-000153.xls
Jan 04, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-19-000154.pdf 0001214659-19-000154.rtf 0001214659-19-000154.xls
Dec 28, 2018	Report of unscheduled material events or corporate event	8-K	View HTML 0001104659-18-074997.pdf 0001104659-18-074997.rtf 0001104659-18-074997.xls

Data provided by Kaleidoscope.

For investor inquiries, please contact:

ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Contacts:
Rx Communications Group
Michael Miller
917-633-6086
mmiller@rxir.com

PRINT PAGE

EMAIL PAGE